Son güncelleme :
19/11/2024
Immünosupresan   Mycophenolate mofetil  
Enjeksiyon
Oral solüsyon / oral çözelti
Çözeltilerin stabilitesi Karışımlardaki stabilitesi Stabiliteyi etkileyen faktörler Uyumluluk Uygulama yöntemi Kaynaklar pdf
   Kimyasal yapı   

Ticari isim   Ticari isim     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cellcept Almanya, Amerika Birleşik Devletleri, Avustralya, Avusturya, Büyük Britanya, Danimarka, Finlandiya, Fransa, Hollanda, İrlanda, İspanya, İsveç, İsviçre, İtalya, Japonya, Kanada, Kolombiya, Lüksemburg, Macaristan, Meksika, Norveç, Polonya, Portekiz, yeni Zelanda, Yunanistan
Micofenolato de mofetilo İspanya
Mycophenolate mofetil Almanya, Belçika, Büyük Britanya
Kaynaklar   Enjeksiyon    Kaynaklar : Mycophenolate mofetil  
tip yayın
1981 Dergi Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C.
Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags.
Am J Health-Syst Pharm 2002 ; 59: 2434-2439.
1982 Dergi Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108 Dergi Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2192 Dergi Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247 Dergi Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3728 Dergi Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3828 afiş Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 afiş So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 Dergi Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4299 Dergi Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M.
Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device.
Biomed Chromatogr 2019 ; 33, 7: e4529.
4528 Dergi Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4698 Dergi Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022

  Mentions Légales